Regeneron Says Phase 3 Data Presented At ATS 2021 Show REGEN-COV Reduced Risk Of Hospitalization Or Death by 70% In Non-hospitalized COVID-19 Patients
Portfolio Pulse from Benzinga Newsdesk
Regeneron presented Phase 3 data at ATS 2021 showing that REGEN-COV reduced the risk of hospitalization or death by 70% in non-hospitalized COVID-19 patients.
May 17, 2021 | 2:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron's REGEN-COV shows promising Phase 3 results, reducing hospitalization or death risk by 70% in non-hospitalized COVID-19 patients.
The positive Phase 3 results for REGEN-COV are likely to boost investor confidence in Regeneron's COVID-19 treatment, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100